{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-25-000066","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2025-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.203012+00:00","generated_at":"2026-05-23T03:52:06.736568+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"USPTO invalidates all challenged claims of Pharmacyclics patent in BeiGene's BRUKINSA® PGR","bullets":["USPTO Final Written Decision invalidates all claims of Pharmacyclics' U.S. Patent No. 11,672,803 challenged by BeiGene in post-grant review.","Patent is part of infringement lawsuit against BeiGene's BTK inhibitor BRUKINSA® (zanubrutinib) filed by Pharmacyclics in 2023.","BeiGene filed PGR petition on November 1, 2023; USPTO decision is appealable by Pharmacyclics."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-25-000066","json":"https://secwatch.observer/filing/0001651308-25-000066.json","markdown":"https://secwatch.observer/filing/0001651308-25-000066.md","text":"https://secwatch.observer/filing/0001651308-25-000066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130825000066/0001651308-25-000066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130825000066/bgne-20250429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T03:52:06.736568+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}